Australia's most trusted
source of pharma news
Posted 20 November 2024 AM
A pending wave of biosimilars set to hit the market over the next five years could unleash a $1 billion windfall with the Generic and Biosimilar Association (GBMA) calling on the Federal Government to beef up policy in the space to fuel better uptake, or Australia risks missing the opportunity.
GBMA CEO, Marnie Peterson, said biosimilars can offset high-cost biologic medicines in the long-term treatment of chronic diseases such as cancers, rheumatoid arthritis, Crohn's disease, and multiple sclerosis.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.